{
    "Recurrence": {
      "Serial CEA elevation": {
        "Workup": [
          "Physical exam",
          "Colonoscopy",
          "C/A/P CT with contrast"
        ],
        "Findings": {
          "Negative findings": {
            "Next step": [
              "Consider FDG-PET/CT",
              "Re-evaluate C/A/P CT with contrast in 3 months"
            ],
            "Further findings": {
              "Negative findings": "End of path",
              "Positive findings": "See treatment for documented metachronous metastases"
            }
          },
          "Positive findings": "See treatment for documented metachronous metastases"
        }
      }
    },
    "Documented metachronous metastases (by CT, MRI, and/or biopsy)": {
      "Workup": "Consider FDG-PET/CT",
      "Resectability assessment": {
        "Resectable": {
          "Molecular Subtype": {
            "pMMR/MSS": "COL-10",
            "dMMR/MSI-H or POLE/POLD1 mutation with ultra-hypermutated phenotype (e.g., TMB >50 mut/Mb)": "COL-15"
          }
        },
        "Unresectable (potentially convertible or unconvertible)": {
          "Molecular Subtype": {
            "pMMR/MSS": "pMMR/MSS treatment (COL-11)",
            "dMMR/MSI-H or POLE/POLD1 mutation with ultra-hypermutated phenotype (e.g., TMB >50 mut/Mb)": [
              "Systemic therapy",
              "COL-D 3 of 12"
            ]
          }
        }
      }
    }
  }
  
